Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bart De Strooper
Inflection points and transitions in Alzheimer’s disease
Abstract Alzheimer’s disease is widely depicted as a linear cascade from amyloid-β accumulation to Tau pathology and neurodegeneration. We propose instead that the disease unfolds through discrete molecular, cellular and network phases organized around biological inflection points. At these thresholds, stress-driven loss of homeostasis produces qualitative shifts in cellular behavior that alters disease progression.
APOE3 and APOE4 human astrocytes differentially modulate Alzheimer’s disease pathology and microglial responses in chimeric mice
|
Keywords Alzheimer's disease AD human astrocytes hAstrocytes human induced pluripotent stem cells hiPSCs chimeric mice apolipoprotein E APOE amyloid-beta Aβ Research topic(s) CP: neuroscience CP: stem cell research Introduction The apolipoprotein E (APOE4) variant of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD).
By Joan Cruz-Sese, Marta Miron-Alcala, Maria Alfonso-Triguero, Jon Olalde, Leire Toscano Ruiz, Laura Escobar, An Snellinx, Takashi Saito, Takaomi C. Saido, Ana M. Aransay, Ibai Diez, Julia TCW, Alison Goate, Bart De Strooper, Elena Alberdi, Amaia Arranz, Nuria Galbis-Gramage, Lorea Cortes, Pranav Preman, Laura Saiz-Aúz, Alberto Rábano-Gutiérrez
|
Cell Reports
Verified
Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
|
Abstract Alzheimer’s disease (AD) is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau. To disentangle these responses, we combined spatial transcriptomics and single-nucleus RNA sequencing of the superior frontal cortex from octogenarians living with or without dementia and from cognitively intact centenarians with comparable Aβ accumulation.
By Ashley Lu, Wei-Ting Chen, Maria Dalby, DIEGO GARCÍA Verified, Marisa Vanheusden, Luuk De Vries, Veerle van Lieshout, Araks Martirosyan, Katleen Craessaerts, Sebastiaan Moonen, Magdalena Zielonka, Iordana Chrysidou, Anke Misbaer, Leen Wolfs, Benjamin Pavie, Dick F. Swaab, Dietmar Rudolf Thal, Inge Huitinga, Annemieke J.M. Rozemuller, Susan Rohde, Marc Hulsman, Henne Holstege, Rita Balice-Gordon, Niels Plath, Mark Fiers, Bart De Strooper
|
Nature
Verified
Aβ plaques induce local pre-synaptic toxicity in human iPSC-derived neuron xenografts
ArticleVolume 21, Issue 1102754Open access 1VIB KU Leuven Center for Brain & Disease Research, Leuven, Belgium 2KU Leuven, Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium 3VIB BioImaging Core, 3000 Leuven, Belgium 4UK Dementia Research Institute, University College London, London, UK Publication History: Received May 16, 2025; Revised November 30, 2025; Accepted December 1, 2025; Published online January 2, 2026 DOI: 10.1016/j.stemcr.2025.102754 External LinkAlso...
The APOE isoforms differentially shape the transcriptomic and epigenomic landscapes of human microglia xenografted into a mouse model of Alzheimer’s disease | Nature Communications
Abstract Microglia play a key role in the response to amyloid beta in Alzheimer’s disease (AD). In this context, the major transcriptional response of microglia is the upregulation of APOE, the strongest late-onset AD risk gene. Of its three isoforms, APOE2 is thought to be protective, while APOE4 increases AD risk. We hypothesised that the isoforms change gene regulatory patterns that link back to biological function by shaping microglial transcriptomic and chromatin landscapes.
The regulatory rollercoaster continues-EMA refuses donanemab
In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval followed a nearly 2-year review process that involved multiple rounds of evaluation, initial rejections, formal appeals, and ultimately a reversal of the initially negative decision.
A versatile mouse model to advance human microglia transplantation research in neurodegenerative diseases
Abstract Background Recent studies highlight the critical role of microglia in neurodegenerative disorders, and emphasize the need for humanized models to accurately study microglial responses. Human-mouse microglia xenotransplantation models are a valuable platform for functional studies and for testing therapeutic approaches, yet currently those models are only available for academic research.
Functional and topological analysis of PSENEN, the fourth subunit of the γ-secretase complex
Abstract: The γ-secretase complexes are intramembrane cleaving proteases involved in the generation of the Aβ peptides in Alzheimer’s Disease. The complex consists of four subunits, with Presenilin, harboring the catalytic site. Here, we study the role of the smallest subunit, PSENEN or Presenilin enhancer 2 (PEN-2), encoded by the gene Psenen, in vivo and in vitro. We find a profound Notch-deficiency phenotype in Psenen-/- embryos confirming the essential role of PSENEN in the γ-secretase complex.
Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer’s disease - Nature Neuroscience
Abstract Early Alzheimer’s disease (AD) is associated with hippocampal hyperactivity and decreased sleep quality. Here we show that homeostatic mechanisms transiently counteract the increased excitatory drive to CA1 neurons in AppNL-G-F mice, but that this mechanism fails in older mice. Spatial transcriptomics analysis identifies Pmch as part of the adaptive response in AppNL-G-F mice.
Neurodegeneration cell per cell
Robinson J.L. Lee E.B. Xie S.X. Rennert L. Suh E. Bredenberg C. Caswell C. van Deerlin V.M. Yan N. Yousef A. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018; 141: 2181-2193https://doi.org/10.1093/brain/awy146 Nelson P.T. Dickson D.W. Trojanowski J.Q. Jack C.R. Boyle P.A. Arfanakis K. Rademakers R. Alafuzoff I. Attems J. Brayne C. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain.
Microglial Expression of the Wnt Signaling Modulator DKK2 Differs between Human Alzheimer’s Disease Brains and Mouse Neurodegeneration Models
Abstract Wnt signaling is crucial for synapse and cognitive function. Indeed, deficient Wnt signaling is causally related to increased expression of DKK1, an endogenous negative Wnt regulator, and synapse loss, both of which likely contribute to cognitive decline in Alzheimer’s disease (AD). Increasingly, AD research efforts have probed the neuroinflammatory role of microglia, the resident immune cells of the CNS, which have furthermore been shown to be modulated by Wnt signaling.
Diabetes and Alzheimer's disease: shared genetic susceptibility?
A search of PubMed using the terms “diabetes” and “Alzheimer's disease” yields nearly 9000 articles, suggesting that a mechanistic link between these two common diseases exists. However, although Alzheimer's disease has been described as type 3 diabetes, 1 Alzheimer's disease is type 3 diabetes-evidence reviewed. no clear mechanistic link between the disorders has been established. 2 Diabetes and Alzheimer's disease: a link not as simple as it seems.
Diabetes and Alzheimer's disease: shared genetic susceptibility?
A search of PubMed using the terms “diabetes” and “Alzheimer's disease” yields nearly 9000 articles, suggesting that a mechanistic link between these two common diseases exists. However, although Alzheimer's disease has been described as type 3 diabetes, 1 Alzheimer's disease is type 3 diabetes-evidence reviewed. no clear mechanistic link between the disorders has been established. 2 Diabetes and Alzheimer's disease: a link not as simple as it seems.
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics - Nature Reviews Drug Discovery
Abstract Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal of amyloid plaque from brains of patients with AD, and the FDA has recently granted accelerated approval to one of these, aducanumab, using reduction of amyloid plaque as a surrogate end point. The rationale for approval and the extent of the clinical benefit from these antibodies are under intense debate.
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics - Nature Reviews Drug Discovery
Abstract Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal of amyloid plaque from brains of patients with AD, and the FDA has recently granted accelerated approval to one of these, aducanumab, using reduction of amyloid plaque as a surrogate end point. The rationale for approval and the extent of the clinical benefit from these antibodies are under intense debate.
Cellular senescence at the crossroads of inflammation and Alzheimer's disease
World Health Organization World Report on Ageing and Health. WHO, 2015 Editorial 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021; 17: 327-406 Lopez-Otin C. et al. The hallmarks of aging. Cell. 2013; 153: 1194-1217 Baker D.J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016; 530: 184-189 Birch J. Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020; 34: 1565-1576 Franceschi C. Campisi J.
Alzheimer's disease
1. Alzheimer Europe Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. 2. Scheltens P Blennow K Breteler MM et al. Alzheimer's disease. Lancet. 2016; 388: 505-517 3. Dubois B Feldman HH Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6: 734-746 4. Dubois B Feldman HH Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010; 9: 1118-1127 5.
Dementia and COVID-19: a health and research funding crisis
Neurological research is at a turning point. Emerging technological advances offer opportunities to understand brain function in health and disease in a way no one could have even dreamed of 5 years ago. With these advances, combined with new methods of targeting the brain with antisense therapy or therapeutic antibodies, we stand on the verge of breakthroughs in treating neurological diseases.
Stem-cell-derived human microglia transplanted into mouse brain to study human disease
Abstract Microglia are critically involved in complex neurological disorders with a strong genetic component, such as Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. Although mouse microglia can recapitulate aspects of human microglia physiology, they do not fully capture the human genetic aspects of disease and do not reproduce all human cell states.
Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets
To provide better prevention and treatment, we need to understand the environmental and genetic risks of Alzheimer’s disease (AD). However, the definition of AD has been confounded with dementia in many studies. Thus, overinterpretation of genetic findings with regard to mechanisms and drug targets may explain, in part, controversies in the field. Here, we analyze the different forms of genetic risk of AD and how these can be used to model disease.
Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer’s Disease
Adaikkan C. Middleton S.J. Marco A. Pao P.-C. Mathys H. Kim D.N.-W. Gao F. Young J.Z. Suk H.-J. Boyden E.S. et al. Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection. Neuron. 2019; 102: 929-943 Alexander G.E. Chen K. Pietrini P. Rapoport S.I. Reiman E.M. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies. Am. J. Psychiatry. 2002; 159: 738-745 Andrews-Zwilling Y. Bien-Ly N. Xu Q. Li G. Bernardo A.
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications
Summary Background Astrocytes, also called astroglia, maintain homoeostasis of the brain by providing trophic and metabolic support to neurons. They recycle neurotransmitters, stimulate synaptogenesis and synaptic neurotransmission, form part of the blood–brain barrier, and regulate regional blood flow. Although astrocytes have been known to display morphological alterations in Alzheimer's disease for more than a century, research has remained neurocentric.
Alzheimer's disease
Although the prevalence of dementia continues to increase worldwide, incidence in the western world might have decreased as a result of better vascular care and improved brain health. Alzheimer's disease, the most prevalent cause of dementia, is still defined by the combined presence of amyloid and tau, but researchers are gradually moving away from the simple assumption of linear causality as proposed in the original amyloid hypothesis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bart
Contact Bart, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack